---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-134757"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:11:50.785248+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OKI-219 well-tolerated in first human trial; no hyperglycemia, Part 1b combo initiated

## Summary
- 17 patients dosed across 300–900 mg BID; no dose interruptions, reductions, or discontinuations.
- Only Grade 1 TRAEs reported (diarrhea, nausea, pruritus); no hyperglycemia observed.
- 900 mg BID achieved steady-state PK with near-continuous EC80 coverage for pAKT inhibition.
- Two HR+/HER2- breast cancer patients on 300 mg showed >7 months stable disease; one had >95% ctDNA reduction.
- Part 1b evaluating OKI-219 + fulvestrant initiated; single-agent/combination data expected 2H 2025.

## SEC filing metadata
- accession: 0000950170-24-134757
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017024134757/0000950170-24-134757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017024134757/okur-20241210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-134757
- JSON: https://secwatch.observer/filing/0000950170-24-134757.json
- Plain text: https://secwatch.observer/filing/0000950170-24-134757.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.